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Approximately 100,000 vascular access proce-
dures are performed yearly in the United States.1
Polytetrafluoroethylene (PTFE) is the most common
material used for prosthetic dialysis access, but 60% of
these grafts fail each year, usually because of stenosis
at the venous end.2-5 Similar lesions develop in PTFE
grafts placed in the arterial circulation, where there is
also a tendency for the distal end of the graft to be
more affected,6 but this process is not as virulent as
access graft stenosis. Proliferation of smooth muscle
cells resulting in intimal hyperplasia in the vein and
the adjacent graft orifice has been described in human
dialysis access stenosis.7 Why the venous end of access
grafts have such a marked propensity for narrowing is
unknown. Features unique to this location include
flow rates that exceed those found in arterial grafts,
dissipation of acoustic (vibratory) energy in the vessel
wall and surrounding tissue, repeated puncture of the
graft, and infusion of processed blood. In addition,
the venous end of the graft may be bathed in mito-
gens released during passage of the blood through the
dialysis tubing or during activation of platelets at the
site of needle puncture. 
We have developed an animal model of access fail-
ure to study this process. Sheep are a useful model for
graft failure, because their coagulation system is simi-
lar to that of humans.8 Furthermore, it is possible to
produce chronic renal failure in sheep to study the
effects of uremia on graft function.9-11 The location
of carotid-to-jugular vein grafts in the neck of these
animals allows the use of grafts that are the same size
as those used clinically and also provides easy access
for graft puncture to simulate dialysis. This model will
be useful in developing strategies for improving access
function, including new graft designs, pharmacology,
and local treatment.
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Purpose: Intimal hyperplasia at the venous anastomosis of dialysis access grafts causes
early failure, although increased flow inhibits intimal hyperplasia in arterial grafts and
after vessel injury. We designed a sheep model to study this process. 
Methods: Polytetrafluoroethylene (PTFE) grafts were placed in the necks of sheep from
the carotid artery to the external jugular vein. Grafts were harvested after perfusion fix-
ation at 4, 8, and 12 weeks and submitted for histologic and immunohistochemical
examination, including morphometry of neointimal lesions.
Results: The venous anastomoses developed thick neointima within the PTFE graft by 4
weeks. Lesions at the venous end were significantly thicker than those at the arterial end
by 8 weeks (1.2 ± 0.1 vs 0.38 ± 0.05 mm, P < .02) and had greater cross-sectional area
at both 4 (0.32 ± 0.21 vs 3.6 ± 0.8 mm2, n = 7, P < .02) and 8 weeks (9.8 ± 1.9 vs 1.1
± 0.7 mm2, n = 7, P < .02). Only one of the four grafts (25%) in the 12-week group
remained patent. Lesions were composed of smooth muscle cells, matrix, and thrombus
of various ages. Cellular proliferation was prominent in neointima adjacent to thrombus
and in granulation tissue surrounding the graft. Organizing thrombus contributed sig-
nificantly to luminal narrowing. 
Conclusion: The sheep model of dialysis access reliably produces venous stenosis within
4 weeks. Lesions develop in the absence of uremia, graft puncture, or dialysis, suggest-
ing that these factors are not necessary for graft failure. The continued presence of
thrombus and high rates of cellular proliferation suggest ongoing injury is an important
cause of lesion formation. This model allows study of the cellular mechanisms of dialy-
sis failure. (J Vasc Surg 1999;30:744-51.)
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MATERIAL AND METHODS
Experimental design and operative procedures.
Columbia crossbred sheep of either sex (Nebeker
Ranch, Lancaster, Calif), weighing between 40 and
60 kg, were fasted overnight, given intramuscular cef-
tiofor (2 mg/kg), and premedicated with intramus-
cular xylazine (0.2 mg/kg) and intravenous ketamine
(10 to 15 mg/kg). After intubation, anesthesia was
maintained with inhalation isoflurane. The neck was
prepared with chlorhexidine, 70% isopropyl alcohol,
and a final application of iodine solution. Cutdowns
were performed on the right carotid artery and the
contralateral external jugular vein. Vessel diameter was
estimated by placing a ruler next to the dissected ves-
sel. Animals were anticoagulated with intravenous
heparin (150 U/kg). By means of a standard vascular
technique, commercially available PTFE grafts, 6 mm
in internal diameter (30 micron internodal distance;
IMPRA, Tempe, Ariz), were sutured end-to-side to
blood vessels with continuous 6-0 polypropylene
suture. The proximal anastomosis was to the right
carotid artery, and the distal anastomosis was to the
contralateral external jugular vein. In preliminary
studies, we found that graft failure caused by kinking
could be avoided by placing the grafts low in the neck
and making a gentle S-shaped curve from the artery
to the vein (Fig 1). Fascia and skin were closed in lay-
ers with bioabsorbable suture. Buprenex was given
(0.005 mg/kg) every 12 hours for 48 hours after
surgery to relieve postoperative pain. Intramuscular
ceftiofur (2 mg/kg) was continued twice a day on
days 1 and 2 and daily on days 3 through 5 after
surgery. Oral aspirin (81 mg/day) was administered 1
day before surgery and once per day throughout the
study. For arteriovenous grafts, patency was checked
daily for the first week and then three times a week by
means of palpation for a thrill and, when the thrill was
not palpated, by means of a hand-held Doppler.
Patency of artery-to-artery grafts was checked three
times a week by means of palpation for a pulse.
Animals were maintained on a standard diet (Purina
Mills Northwestern Pride Diet 32B4 pellets and hay
cubes twice per day).
Animal care complied with the “Principles of
Laboratory Animal Care” formulated by the National
Society for Medical Research and the “Guide for the
Care and Use of Laboratory Animals” (NIH Pub-
lication No. 86-23, revised 1985).
At the time of graft harvest, the animals were anti-
coagulated with intravenous heparin (150 U/kg) and
then killed by an overdose of sodium pentobarbital.
The neck was then rapidly opened, and the carotid
artery supplying the graft was cannulated well proxi-
mal to the graft and ligated beyond it. The recipient
artery or vein was also dissected out well beyond the
anastomosis and ligated above and below. Drainage
was allowed through an incision in this vessel while
the graft was perfused at physiologic pressure (100
mm Hg), first with Ringers lactate solution until
blood was cleared and then with 10% neutral-buffered
formalin. Drainage was clamped during the last 5
minutes of perfusion. Grafts and adjacent vessels were
then excised and further immersion fixed for a mini-
mum of 24 hours in the same fixative.
Blood flows were measured at the time of graft
implantation by means of a Transonic ultrasound
flowmeter (Transonic Systems, Ithaca, NY) in two
animals during this experiment and in six additional
animals undergoing the same procedure for another
experiment. The flow probe was placed on the prox-
imal carotid artery supplying the graft. Flows were
measured with and without occlusion of the graft.
Graft flow was calculated as flow with the graft open
minus flow with the graft closed.
Histology processing and analysis. Cross sec-
tions were made of the artery and vein 1 cm proximal
and distal to the anastomoses, through the toe of the
grafts, and at 0.5-cm intervals along the graft (Fig 2).
Tissues were embedded in paraffin and cut in 5-µm
thicknesses for microscopic examination with hema-
toxylin and eosin and Masson’s trichrome stains. Area
measurements were made from captured images
obtained with a color video camera attached to a stan-
dard Olympus light microscope by using computer-
assisted morphometry (Image Pro Plus, Media
Cybernetics, Silver Spring, Md). With the highest
magnification that allowed the entire graft section to
be visualized in one field, the area of the neointima was
manually traced. Thickness of the neointima adjacent
to the graft-vessel junction was also measured at two
locations 180 degrees apart from at least one section
Fig 1. Diagram of graft configuration in the neck. Arrows
indicate direction of blood flow.
JOURNAL OF VASCULAR SURGERY
746 Kohler and Kirkman October 1999
through each anastomosis (Fig 3). Maximum vein-wall
thickness was measured in sections proximal and distal
to the venous anastomosis. Cell types were identified
by means of immunohistochemistry with antibodies
against smooth-muscle-cell actin (Vector Laboratories,
Burlingame, Calif) and human anti-macrophage
(HAM-56). Cell proliferation was identified with a
monoclonal antibody to the Ki-67 antigen, which is
present in the nucleus throughout cell division.12
Immunostaining was accomplished with anti-mouse
secondary antibodies (Vector Laboratories), avidin-
biotinylated peroxidase, and diaminobenzidine as the
chromogen. Positive controls were a normal artery
served for α-actin and sheep gut crypt cells served for
Ki-67. A human antibody was substituted for the pri-
mary antibody as a negative control for Ki-67.
Statistics. Results are reported as mean ± SEM.
Comparisons between paired measurements at the
proximal and distal ends of grafts were made with the
Wilcoxon signed rank test and between group means
with the Mann-Whitney test (SPSS, Version 7.5,
SPSS, Chicago, Ill).
RESULTS
The animals weighed from 29 to 51 kg (mean, 38
± 9 kg) at the time of surgery and gained an average of
5.8 kg in the 4-week group and 4.8 kg in the 8-week
group. In the 1- and 2-month groups, four arteriove-
nous grafts thrombosed (at 2, 3, 3, and 7 days post-
operatively) and were excluded from further analysis.
Seven grafts remained patent in the 4-week group, and
seven remained patent in the 8-week group. Three of
four grafts placed for the 3-month group failed
between 2 and 3 months, for a failure rate of 75%.
Failed grafts were excluded from further analysis,
because organizing thrombus that resulted from graft
failure could not be distinguished from that found at
the venous anastomosis of functioning grafts. The
remaining patent grafts were harvested at 4 weeks (n =
7), 8 weeks (n = 7), and 12 weeks (n = 1). 
Graft flow at the time of operation was 460 ±
220 mL/min (mean ± SD, n = 8). Graft length
ranged from 11.1 to 14.0 cm (mean, 12.9 ± 0.9
cm). Vessel diameter at the time of implantation was
significantly greater for the veins than the arteries
(8.6 ± 0.3 mm vs 5.1 ± 0.1 mm, n = 8, P < .001). 
There were only focal areas of thickening in the
vein segments proximal and distal to the anasto-
mosis (sections V-1 and V-2; mean, 0.41 ± 0.47
mm; normal vein thickness is 0.07 ± 0.01 mm).
The midgraft sections (V-9) had a pseudointima
like that of standard arterial PTFE grafts, consist-
ing of a fibrin layer with scant cellularity. In some
grafts, thrombus extended into the midportion.
Limited ingrowth of neointima was seen at the
arterial end of the grafts (Fig 3). This lesion was
similar to that described earlier for PTFE grafts
placed in the arterial circulation.13 It was covered
by a continuous layer of endothelium-like cells.
The underlying tissue was cellular and consisted
primarily of smooth muscle cells (α-actin positive)
with some macrophages (HAM-56 positive) and
capillary ingrowth. These lesions extended only a
short distance onto the graft (average, less than 1
cm). Thickness of neointima at the artery-to-graft
interface did not change significantly between 4
and 8 weeks and was similar in the 12-week speci-
men (from the arterial equivalent of section V-3;
Fig 2. Diagram of the anastomosis of graft to vessel, indi-
cating the location of histologic sections.
Fig 3. Neointima at arterial anastomosis. Arrowheads indi-
cate where measurement of intimal thickness was made
(original magnification, 32×; hematoxylin and eosin).
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Table I). Thrombus was scant at this anastomosis,
and the lumen was not compromised.
In contrast to the arterial end of the grafts, the
venous end developed lesions that narrowed the
lumen (Fig 4). Thrombus, primarily at the venous
anastomosis, was a prominent feature at all times.
This thrombus often extended over the graft for sev-
eral centimeters from the venous anastomosis.
Lesions of neointimal hyperplasia similar to those
found at the arterial end of the grafts also occurred
at the venous anastomosis. Neointimal thickness
(measured from section V-3) and area (measured
from section V-4) were significantly greater at the
venous anastomosis than at the corresponding loca-
tions of the arterial anastomosis (Tables I and II).
Between 4 and 8 weeks, neointimal thickness tripled
(P < .02; Table I) and neointimal area doubled (P <
.02; Table II). 
The cellular portion of the neointima was pre-
dominantly composed of smooth muscle cells (Fig 5).
Active organization of thrombus was evident. Mac-
rophages, smooth muscle cells, and capillaries could
be seen invading thrombus from adjacent areas of
neointima. Cellular proliferation was prominent in
these regions and primarily involved the neovascula-
ture and inflammatory cells invading the thrombus
(Figs 6 and 7). Cellular proliferation was also active in
macrophages on the outer surface of the PTFE and in
cells in the leading edge of neointima at the arterial
end of the grafts. Various stages of thrombus organi-
zation were found in contiguous areas, and extensive
angiogenesis occurred throughout. The predominant
cell type of the lesions was smooth muscle (α-
actin–positive cells), but areas of thrombus organiza-
tion and neovascularity often contained mostly
inflammatory cells and α-actin–negative stromal cells.
Small islands of bone formation were noted in
some specimens at 8 weeks. The appearance of bone
was complete, with a calcified matrix containing
lacunas with osteogenic cells and a lamina limitans.
Osteogenesis tended to occur in areas particularly
rich in microvessels. Cells surrounding these areas of
ossification did not stain positively with either the α-
actin or anti-macrophage antibody.
Fig 4. Neointimal lesion at the venous end of a 1-month
graft demonstrating acute thrombus (solid arrowhead), bone
formation (open arrowhead), abundant neovascularization
(black dot), and polytetrafluoroethylene graft (white asterisk;
original magnification, 64×; hematoxylin and eosin).
Fig 5. High-power view of the neointima near the toe of a
venous anastomosis. Dark staining of the cytoplasm of most
cells in this field is caused by positive immunoreactivity with
the α-actin antibody (original magnification, 250×).
Table I. Neointimal thickness at anastomoses of
arteriovenous grafts
Weeks No. Proximal (mm) Distal (mm) P value
4 7 0.50 ± 0.05 0.35 ± 0.05 < .05
8 7 0.38 ± 0.05 1.2 ± 0.1* < .02
12 1 0.26 0.90
Data reported as means ± SEM.
*P < .01, 4 weeks vs 8 weeks.
Table II. Neointima areas of arteriovenous grafts
Weeks No. Proximal (mm2) Distal (mm2) P value
4 7 0.32 ± 0.21 3.6 ± 0.8 < .02
8 7 1.1 ± 0.7 9.8 ± 1.9* < .02
12 1 4.1 16.9
Data reported as means ± SEM.
*P < .05, 4 weeks vs 8 weeks.
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DISCUSSION
Although other methods have been used to study
arteriovenous bridge grafts, the sheep model is the
first to develop rapid luminal narrowing. It is perplex-
ing that the hyperplastic response is so robust in these
high-flow fistulas, because increased flow inhibits inti-
mal hyperplasia in PTFE grafts placed in the arterial
circulation14-16 and after vascular injury.17 However,
it is in keeping with the observation that clinical arte-
riovenous grafts fail at a much greater rate than simi-
lar grafts placed in the arterial circulation. The most
obvious differences between the two types of graft are
the distal anastomosis of arteriovenous grafts being to
a vein rather than an artery, flow being of greater
magnitude and unidirectional rather than bidirection-
al, and pressure being less. In our model, organization
of thrombus is a critical factor in lesion formation. 
Stenosis forms at the venous anastomosis of sheep
arteriovenous grafts within 4 to 8 weeks. The arterial
anastomosis remains widely patent. Lesions at the
venous end of the sheep grafts are remarkably similar
to those found in human access failure.7 In both
cases, the lesions consist primarily of smooth muscle
cells and have prominent areas of neovascularization
associated with cell proliferation. Macrophages and
lymphocytes are also present, particularly in associa-
tion with thrombus and microvessels. Thrombosis is
an important aspect of the sheep model that is not
described in human specimens, but it may play a role
in clinical access failure, as it does in the sheep. This is
suggested by the finding of hemosiderin, a marker for
previous thrombosis, in the media and adventitia of
clinical specimens.7 Abnormally high and disordered
flow and endothelial injury are likely causes of this
thrombosis, which is present as long as 12 weeks after
graft placement in sheep. The leading edge of new
endothelium moving upstream onto the graft surface
may be lifted off by the shear forces of the opposing
high, fistula flow. Endothelium may be further dam-
aged by turbulence. Injury plus altered flow cause
thrombosis, which is exacerbated by high flow.18,19
In the midgraft, thrombus alone forms the
pseudointima and does not narrow the lumen, but at
the venous anastomosis thrombus organization con-
tributes significantly to lumen reduction. Thrombus
occurs at the interface of blood with most biomate-
rials. PTFE is less thrombogenic than other materi-
als, such as Dacron, but platelet deposition and fib-
rin formation still occur. It is quite possible that
Fig 6. Magnified view of the juncture between thrombus
on the surface of the lumen and the underlying neointima.
Inflammatory cells, which are mostly macrophages, are
invading the thrombus. The lesion is heavily neovascular-
ized (original magnification, 125×; hematoxylin and eosin).
Fig 7. Section of neointima near the venous anastomosis
demonstrating frequent cellular proliferation (arrowhead,
positive immunoreactivity in the cell nucleus with the anti-
body Ki-67; original magnification, 250×).
improving the blood-biomaterial interaction could
decrease thrombus formation and enhance graft per-
formance. A graft that exactly mimics a native artery
should have excellent patency, because arteriovenous
fistulae made of native vessels do not have the prob-
lem of aggressive neointimal thickening seen when
prosthetic material is used. Surface modification of
the prosthetic may improve the blood-biomaterial
interaction. For example, treatment of PTFE arteri-
ovenous grafts in dogs with the cell-membrane lipid
phosphorylcholine reduces platelet deposition,
neointimal area, and cellular proliferation.20
When thrombus forms, it is invaded by macro-
phages and organized into a cellular lesion by
ingrowth of neovasculature and smooth muscle cells
from the adjacent vessel. The fibrin meshwork acts as
a scaffold for ingrowth of cells and subsequent orga-
nization of the lesion, which at late stages has the
characteristics of neointimal hyperplasia. Activated
macrophages, platelets, and smooth muscle cells all
release cytokines, such as platelet-derived growth fac-
tor, fibroblast growth factor, and transforming
growth factor, which stimulate cell proliferation,
migration, and angiogenesis. Thrombin generated
during thrombosis may also stimulate smooth muscle
cell growth and migration.21 This rich milieu of
growth factors may also include bone morphogenic
proteins that cause the observed areas of ossification.
Osteocytes could be derived from primitive mes-
enchymal cells, possibly pericytes in new blood ves-
sels.22 Bone formation is not a common feature of
clinical dialysis access failure, but it does occur in ath-
erosclerotic plaque and has been described in explant-
ed human PTFE grafts.23,24 We found it in the neoin-
tima of a few of the grafts removed at 8 weeks, but it
was not a prominent feature in the sheep model.
Fistula flow alone is not sufficient to cause distal
stenosis. Thrombosis and lumen-narrowing lesions
do not occur in high-porosity artery-to-artery
PTFE grafts supplying a distal arteriovenous fistula
in a primate model.15 In fact, high flow suppresses
neointimal growth in this system, perhaps because
of the nitric oxide production of the endotheli-
um.25 Several differences between this and the
sheep model may explain this discrepancy. First, the
high-porosity grafts form a complete endothelial
lining caused by capillary ingrowth throughout
their length. This lining may be more resistant to
flow-induced damage. Second, cells in the wall of
the recipient artery may not be injured as much as
cells in the thin-walled vein. Finally, turbulence may
be significantly less in grafts supplying a distal fistu-
la than in arteriovenous grafts. These three possibil-
ities can all be tested in our model. 
The lesions that developed in the sheep grafts
were primarily in the ostium and did not cause
appreciable thickening of the adjacent vein, in strik-
ing contrast to the typical clinical lesion, in which
there is narrowing of the vein adjacent to the anas-
tomosis in addition to narrowing within the graft.
This may reflect our model being fairly acute, where-
as clinical specimens are from end-stage lesions that
have typically formed in longer periods. Venous
thickening does occur in long-term, native arteri-
ovenous fistulae in sheep.26 Another reason the vein
does not thicken appreciably may be the large diam-
eter of the external jugular vein in the sheep (7 to 10
mm vs 3 to 4 mm for recipient veins used clinically).
Turbulence and high shear may be rapidly dissipated
in this large vein. This is in keeping with the findings
of Fillinger and coworkers, who have shown that
reducing flow in canine arteriovenous grafts, either
by means of banding or by using a tapered graft with
a narrowed arterial inlet, results in less thickening of
the vein wall.27,28 The extent of vibration in the sur-
rounding tissues correlated best with wall thicken-
ing, suggesting that vibration injury contributes to
intimal hyperplasia. Such vibration injury may con-
tribute to endothelial damage and the resulting
thrombosis, which occurred in our studies.
As with most animal models of clinical problems,
there are differences that must be considered when
using these findings to understand human lesions.
These include the prominence of thrombus forma-
tion, the particularly rapid failure rate, the finding of
occasional ossification, and the lack of venous thick-
ening. However, the sheep model and human access
failure both have aggressive venous stenosis in condi-
tions of high flow, and the resulting lesions have very
similar histology and patterns of cellular prolifera-
tion. Whether or not it exactly reproduces the clini-
cal problem, the sheep model will be helpful for test-
ing hypotheses about the causes of failure, such as the
role of high flow, vein-wall injury, and thrombus
organization. The finding of significant stenosis at
the venous end of these grafts in the absence of ure-
mia or graft puncture for dialysis suggests that these
factors may not be of prime importance in access fail-
ure, although they may contribute to lesion forma-
tion or enhance the tendency for smooth muscle cell
proliferation. The sheep model should also be useful
for assessing graft modifications or therapies
designed to improve function. Among the many pos-
sible methods to prevent access failure that can be
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addressed in this model are: (1) modification of the
graft itself to reduce thrombosis and encourage
transmural ingrowth of capillaries for complete
endothelial surfacing that may be more stabile in
high and unsteady flow conditions; (2) local or sys-
temic pharmacology to limit cell proliferation or
thrombosis; (3) local radiation treatment; (4) seeding
or sodding of the graft surface with endothelial cells;
and (5) use of oligonucleotides or genetically modi-
fied cells to deliver specific gene products to affect
cell growth, proliferation, or matrix deposition. 
CONCLUSION
The sheep model of dialysis access reliably pro-
duces venous stenosis within 8 weeks. Lesions are
composed mainly of smooth muscle cells and throm-
bus. Thrombus organization contributes significant-
ly to luminal narrowing. Neovasculature and cell
proliferation are prominent features in regions of
thrombus organization. Instability of the endotheli-
um at the venous anastomosis, perhaps related to
unfavorable shear stress working against the ingrow-
ing endothelial edge, may contribute to continued
thrombosis. Rapid lesion formation in the absence
of uremia, graft puncture, or dialysis suggests that
these factors may not be the usual cause of dialysis
access failure. Methods to stabilize the ingrowing
endothelium and reduce thrombosis may improve
graft function.
We thank Susan Rozell for her expert technical assis-
tance and Marina Furgeson for histologic preparations.
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CORRECTION
Table II contained incorrect information in the January 1999 article entitled “Redo carotid surgery: An
analysis of materials and configurations used in carotid reoperations and their influence on perioperative
stroke and subsequent recurrent stenosis” by Caron B. Rockman, MD, et al (J Vasc Surg 1999;29:72-81).
The errors were made in the raw numbers provided by the authors and not in the percentages or the statis-
tical evaluation, so the stated conclusions should remain valid. The correct table appears below.
Table II,A. Comparison of perioperative outcome with respect to surgical techniques and materials
Patch angioplasty Interposition grafting With vein With prosthetic
(n = 47) (n = 35) P value (n = 35) (n = 47) P value
Perioperative CVA or TIA 1 (2.1%) 3 (8.6%) .2 1 (2.9%) 3 (6.4%) .42
CVA, Cardiovascular accident; TIA, transient ischemic attack.
Table II,B. Comparison of late outcome with respect to surgical techniques and materials
Patch angioplasty Interposition grafting With vein With prosthetic
Late failure (n = 41) (n = 32) P value (n = 30) (n = 43) P value
All late failures 6 (14.6%) 3 (9.4%) .38 8 (26.7%) 1 (2.3%) .002
No. of restenoses >50% 3 1 4 0
No. of total occlusions 3 2 4 1
